Mylan’s EpiPen sales have taken a hit By: MarketWatch May 10, 2017 at 09:35 AM EDT Mylan’s offering a cheaper version of the treatment, and new competition have affected earnings results. Read More >> Related Stocks: CVS Health Corp Mylan Standard & Poors 500